BioRestorative Therapies (BRTX) announced that the European Patent Office has issued a Notice of Allowance for a new patent application covering key aspects of the company’s allogeneic, off-the-shelf ThermoStem metabolic disease platform. Claims granted under the new patent cover a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX: